

Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

NCT03308916

Status	RECRUITING
Phase	Not Applicable
Sponsor	Maja Thiele
Enrollment	6,500 participants

Key Eligibility Criteria

Inclusion (6)

- Age 30-75 years (except the general population, which should be aged 40-75)
 - Informed consent to study investigations
 - Ability to read and write Danish AND (only at-risk patients)
 - Prior or current alcohol overuse, defined as an average intake of e24 grams/day (14 units/week) for women and e36 grams/day (21 units/week) for men, for at least 5 years; OR
 - Presence of the metabolic syndrome defined by central obesity plus any two of the following four metabolic risk factors: (a) raised triglycerides, (b) reduced HDL cholesterol, (c) raised blood pressure and (d) raised fasting plasma glucose;[38] OR
- ... and 1 more (see full listing online)

Exclusion (10)

- We will exclude patients from screening in case of:
 - Evidence of decompensated liver disease, defined by clinically obvious ascites, overt hepatic encephalopathy, jaundice or large esophageal varices with/without variceal bleeding.
 - Known concurrent liver disease other than ALD and NAFLD.
 - Cancer or other debilitating disease with an expected survival of less than 12 months.
 - Inability to comply with the study protocol.
- ... and 5 more (see full listing online)

Locations (1 total)

Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark

<https://clinicaltrials.gov/study/NCT03308916>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).